Former CEO resigns from Molecular Insight board

TriMed Staff | | Health Imaging | Cardiac Imaging
David S. Barlow has resigned from the board of directors of Molecular Insight Pharmaceuticals, a Cambridge, Mass.-based developer of radiotherapeutics and molecular imaging agents in oncology and cardiology.

The resignation went into effect Dec. 30, 2008 and was related to Barlow’s “disagreements with the board,” he said in a statement.

Barlow is the former CEO of Molecular Insight. In September 2008, the company announced that Barlow would immediately be replaced by interim CEO and chairman of the board John Babich, who formerly served as president and chief scientific officer of Molecular Insight before taking the helm.

TriMed Staff

Related Content

New AI program delivers rapid, accurate echo video assessments
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage
New scoring system accurately predicts coronary risk in women
Philips, Mayo Clinic using AI to improve cardiac MRI technology
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access
FDA clears AI screening tool for cardiac amyloidosis

Around the web

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.